MedTrace Logo

Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers

NCT01044836 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2014-07-15

No results posted yet for this study

Summary

The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.

Conditions

  • Healthy

Interventions

BIOLOGICAL

HD203

Injectable form

Sponsors & Collaborators

  • Hanwha Chemical

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044836 on ClinicalTrials.gov